GlassScriptPhysician profile
David Awyn Hall
NPI 1275598757
$8,559.09
in general payments reported to CMS, 2019-2025
42 companies · $1,610 in 2025
The $1,610 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,065 · 2020: $597 · 2021: $1,320 · 2022: $1,020 · 2023: $1,213 · 2024: $1,734 · 2025: $1,610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,521 · Education: $36.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,521.40 |
| Education | $36.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,471.84 | 2019-2025 | |
| Janssen Biotech, INC. | $758.93 | 2019-2025 | Stelara, Tremfya, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $527.94 | 2019-2024 | Trulance, Xifaxan |
| Lilly USA, LLC | $461.49 | 2023-2025 | Omvoh |
| Takeda Pharmaceuticals U.S.A., INC. | $459.79 | 2019-2025 | Entyvio |
| Pfizer INC. | $376.59 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $339.88 | 2022-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $262.95 | 2021-2023 | Zeposia |
| Ironwood Pharmaceuticals, INC | $252.07 | 2019-2021 | |
| Ardelyx, INC. | $251.65 | 2022-2025 | Ibsrela |
| Enterra Medical, INC. | $243.33 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $210.68 | 2023-2025 | Voquezna |
| Axonics, INC. | $182.84 | 2024 | Axonics |
| Boston Scientific Corporation | $162.63 | 2019-2021 | |
| Qol Medical, LLC | $157.20 | 2019-2024 | Sucraid, Sucraid |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $137.13 | 2019-2024 | Dificid, Zinplava |
| Janssen Scientific Affairs, LLC | $133.50 | 2025 | Stelara, Remicade, Tremfya |
| Madrigal Pharmaceuticals | $127.06 | 2024-2025 | Resmetirom, Rezdiffra |
| Redhill Biopharma INC. | $116.14 | 2020-2023 | Talicia |
| Amgen INC. | $112.30 | 2021-2023 | Avsola, Amjevita |
| Daiichi Sankyo INC. | $104.78 | 2019-2021 | |
| Celgene Corporation | $74.67 | 2021-2023 | Zeposia |
| Organon LLC | $67.50 | 2021-2022 | |
| Genzyme Corporation | $63.18 | 2025 | |
| Intercept Pharmaceuticals, INC. | $58.73 | 2019-2025 | |
| Braintree Laboratories, INC. | $56.02 | 2020-2024 | Suflave, Sutab |
| Ethicon US, LLC | $50.77 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $39.54 | 2022-2024 | Givlaari |
| Mallinckrodt Hospital Products INC. | $39.17 | 2024-2025 | Terlivaz |
| Aimmune Therapeutics, INC. | $32.71 | 2023-2024 | |
| Nestle Healthcare Nutrition INC. | $31.12 | 2021-2022 | |
| Fresenius Kabi USA, LLC | $30.42 | 2023 | Idacio |
| Novo Nordisk INC | $26.45 | 2025 | Wegovy |
| Endogastric Solutions, INC | $23.98 | 2019 | |
| Shionogi INC | $20.40 | 2019 | |
| Evoke Pharma, INC. | $18.34 | 2021 | |
| Celltrion USA INC. | $17.19 | 2025 | Vegzelma |
| Astellas Pharma US INC | $15.31 | 2023 | Veozah |
| Allergan, INC. | $14.64 | 2019 | |
| Vivus LLC | $14.15 | 2025 | Pancreaze |
| Ferring Pharmaceuticals INC. | $14.08 | 2023 | Rebyota |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$26,812.13 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.